Please assess the completion status of the following clinical trial:

Trial Title: Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Chronic HIV-1 infected individuals on HAART (with no change in treatment within 4 weeks of study entry) and willing to continue therapy for the duration of the study.~2. HIV viral load less than 200 copies/ml for more than 6 months at time of screening.~3. Nadir CD4 count less than 350 and current CD4 counts greater than 100 cells/ul.~4. Hs-CRP levels above 2mg/L.~5. Willingness to use a method of contraception during the study period.~6. Willingness to comply with study evaluations for LP sub-study.~7. Karnofsky performance score of 80 or higher.~8. If female, willing to undergo pregnancy testing on a monthly basis and not breastfeeding.~9. Hemoglobin greater than or equal to 9.0 g/dL for female and 10.0 g/dL for male subjects.~10. men and women 18 years or older.~Exclusion Criteria:~1. Concomitant use of fibric acid derivatives or other lipid lowering agents including patients on statins and Ezetimibe.~2. Use of any anti-inflammatory drugs (OTC or prescription) on a daily basis.~3. Pregnancy or breastfeeding~4. Active drug use or alcohol abuse/dependence which in the opinion of researchers will interfere with the patients' ability to participate in the study.~5. Allergy or hypersensitivity to Atorvastatin or any of its components.~6. History of myositis or rhabdomyolysis with use of any statins.~7. Patients who are on concurrent immunomodulatory agents, including systemic corticosteroids (nasal or inhaled) will be ineligible for 3 months after completion of therapy with the agent.~8. History of inflammatory muscle disease such a poly or dermatomyositis.~9. Serious intercurrent illness requiring systemic treatment and/or hospitalization within 30 days of entry.~10. Evidence of active opportunistic infections requiring treatment or neoplasms that require chemotherapy during study period.~11. CPK greater than 3 times the ULN.~12. Known active liver disease or AST/ALT greater than 3 times the ULN.~13. Renal insufficiency, indicated by serum creatinine greater than 2mg/dL.~14. Absolute neutrophil counts less than 1000/ul; hemoglobin less than 10g/dL for males and less than 9g/dL for females; platelet counts less than 100,000/mm3.~15. Documented HCV infection.~16. NYHA class III or IV congestive heart failure.~17. Active IV drug use within 1 year prior to entry.~18. For LP sub-study, allergy to Lidocaine.~19. Coronary artery disease or equivalent including Diabetes mellitus.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: ACTIVE_COMPARATOR): Participants were given atorvastatin for 12 weeks at various doses based on their specific HAART treatment.
- Placebo (Type: PLACEBO_COMPARATOR): Participants were given Placebo tablets for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete